Capital International Investors
CYTK icon

Capital International Investors’s Cytokinetics CYTK Stock Holding History

Capital International Investors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111M Sell
1,305,848
-32,955
-2% -$2.37M 0.02% 281
2026
Q1 		$88.2M Buy
1,338,803
+160,023
+14% +$10.2M 0.02% 292
2025
Q4 		$74.9M Hold
1,178,780
– – 0.01% 321
2025
Q3 		$64.8M Buy
1,178,780
+10,670
+0.9% +$440K 0.01% 323
2025
Q2 		$38.6M Hold
1,168,110
– – 0.01% 350
2025
Q1 		$46.9M Buy
1,168,110
+71,946
+7% +$3.31M 0.01% 329
2024
Q4 		$51.6M Buy
+1,096,164
New +$56.9M 0.01% 338

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors's CYTK Position: Q2 2026 in Review

Capital International Investors reduced its Cytokinetics (CYTK) stake by 2.5% in Q2 2026, selling an estimated $2.37M and leaving 1,305,848 shares worth $111M. The position accounts for 0.02% of the portfolio, ranked #281.

Capital International Investors first reported a position in CYTK in Q4 2024 and has held it in 7 quarters since. 325 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Capital International Investors held 1,305,848 shares of Cytokinetics worth $111M as of Q2 2026.
  • Capital International Investors sold 32,955 Cytokinetics shares in Q2 2026, an estimated $2.37M.
  • Cytokinetics made up 0.02% of Capital International Investors's portfolio in Q2 2026, its #281 holding.
  • Capital International Investors first reported a position in Cytokinetics in Q4 2024 and has held it in 7 quarters since.
  • 325 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Capital International Investors's 13F filing for Q2 2026, filed 12 Aug 2026.